Washington, Apr 20 : In a study, led by an Indian-origin scientist, researchers have found a combination therapy, which could reduce cancer stem cells and stop the growth pancreatic cancer-one of the deadliest cancers.
Rajesh Kumar N. V., Ph. D., a faculty member at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, led the study.
He said that a combination therapy using tigatuzumab, a novel humanized death receptor-5 (DR-5) agonist antibody, along with gemcitabine, could result in reducing pancreatic cancer stem cells to achieve tumour remission and prevent tumour recurrence.